SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tktom who wrote (3956)10/19/2015 6:37:07 PM
From: Biomaven  Read Replies (1) of 4474
 
The company doesn't have the money or the expertise to develop pona in any neurodegenerative disease. This is something best left to ISPs.

The potential in ALS is purely theoretical - it is because pona inhibits RIPK1 and this is a crucial kinase involved with necroptosis, which researchers at Columbia discovered was how the motor neurons appeared to be killed. I actually emailed the researcher there about pona as a RIPK inhibitor some time back - don't know if they ever tried it in their stem-cell model. But at this point it is only speculation - have to actually run the experiment to see if it works in their model.

Likely not particularly relevant to the company's stock price in my view, although that could change if further research gets published.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News